Glioblastoma Multiforme Clinical Trials

34 studies are recruiting for glioblastoma multiforme in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

   The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement.

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Johns Hopkins Medical Institution, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT05083754 on ClinicalTrials.gov

2. Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

   This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tecentriq), an FDA appr…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Stony Brook University Hospital, Stony Brook, New York

   Run by

   Stony Brook University

   See if you can join NCT05423210 on ClinicalTrials.gov

3. Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

   The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Run by

   Henry Ford Health System

   See if you can join NCT05686798 on ClinicalTrials.gov

4. Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

   This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   Jackson Memorial Hospital, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT05956821 on ClinicalTrials.gov

5. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

   To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

   Locations

   35 in total

   Run by

   Apollomics Inc.

   See if you can join NCT03175224 on ClinicalTrials.gov

6. Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

   The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Hospital, Detroit, Michigan

   Locations

   8 in total

   Run by

   Orbus Therapeutics, Inc.

   See if you can join NCT05879367 on ClinicalTrials.gov

7. The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

   Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molec…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06283927 on ClinicalTrials.gov

8. The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

   There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internation…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06146725 on ClinicalTrials.gov

9. The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

   There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This stu…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06146738 on ClinicalTrials.gov